RVPH
Price
$0.59
Change
-$0.09 (-13.24%)
Updated
Oct 27, 04:59 PM (EDT)
Capitalization
65.06M
21 days until earnings call
Intraday Buy/Sell Signals
XENE
Price
$41.89
Change
+$1.13 (+2.77%)
Updated
Oct 27, 04:59 PM (EDT)
Capitalization
3.14B
9 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

RVPH vs XENE

Header iconRVPH vs XENE Comparison
Open Charts RVPH vs XENEBanner chart's image
Reviva Pharmaceuticals Holdings
Price$0.59
Change-$0.09 (-13.24%)
Volume$47.66K
Capitalization65.06M
Xenon Pharmaceuticals
Price$41.89
Change+$1.13 (+2.77%)
Volume$15.8K
Capitalization3.14B
RVPH vs XENE Comparison Chart in %
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RVPH vs. XENE commentary
Oct 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVPH is a Hold and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 27, 2025
Stock price -- (RVPH: $0.68 vs. XENE: $40.76)
Brand notoriety: RVPH and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RVPH: 285% vs. XENE: 117%
Market capitalization -- RVPH: $65.06M vs. XENE: $3.14B
RVPH [@Biotechnology] is valued at $65.06M. XENE’s [@Biotechnology] market capitalization is $3.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RVPH’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • RVPH’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than RVPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RVPH’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • RVPH’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RVPH is a better buy in the short-term than XENE.

Price Growth

RVPH (@Biotechnology) experienced а +17.53% price change this week, while XENE (@Biotechnology) price change was -2.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.59%. For the same industry, the average monthly price growth was +11.23%, and the average quarterly price growth was +64.97%.

Reported Earning Dates

RVPH is expected to report earnings on Nov 17, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.14B) has a higher market cap than RVPH($65.1M). XENE YTD gains are higher at: 3.980 vs. RVPH (-62.691). RVPH has higher annual earnings (EBITDA): -27.07M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. RVPH (10.4M). RVPH has less debt than XENE: RVPH (113K) vs XENE (8.72M). XENE has higher revenues than RVPH: XENE (7.5M) vs RVPH (0).
RVPHXENERVPH / XENE
Capitalization65.1M3.14B2%
EBITDA-27.07M-315.5M9%
Gain YTD-62.6913.980-1,575%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash10.4M488M2%
Total Debt113K8.72M1%
FUNDAMENTALS RATINGS
RVPH vs XENE: Fundamental Ratings
RVPH
XENE
OUTLOOK RATING
1..100
9023
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10035
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3644
P/E GROWTH RATING
1..100
106
SEASONALITY SCORE
1..100
1950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (73) in the Biotechnology industry is in the same range as RVPH (94) in the null industry. This means that XENE’s stock grew similarly to RVPH’s over the last 12 months.

XENE's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for RVPH (100) in the null industry. This means that XENE’s stock grew somewhat faster than RVPH’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as RVPH (100) in the null industry. This means that XENE’s stock grew similarly to RVPH’s over the last 12 months.

RVPH's Price Growth Rating (36) in the null industry is in the same range as XENE (44) in the Biotechnology industry. This means that RVPH’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is in the same range as RVPH (10) in the null industry. This means that XENE’s stock grew similarly to RVPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RVPHXENE
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
73%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 13 days ago
72%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 4 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SPOFF0.18N/A
+2.25%
EARTHLABS INC.
AFSIN14.060.01
+0.07%
AmTrust Financial Services, Inc.
RGNLF8.78N/A
N/A
REGIONAL S A
EMCHF0.64N/A
N/A
EML Payments Ltd.
TLTZY8.05-0.14
-1.71%
Tele2 AB

RVPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, RVPH has been loosely correlated with ALT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RVPH jumps, then ALT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVPH
1D Price
Change %
RVPH100%
+19.00%
ALT - RVPH
50%
Loosely correlated
-0.25%
INDP - RVPH
30%
Poorly correlated
+2.25%
GYRE - RVPH
30%
Poorly correlated
-0.73%
INM - RVPH
29%
Poorly correlated
+1.97%
NEVPF - RVPH
27%
Poorly correlated
N/A
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-1.07%
NUVL - XENE
62%
Loosely correlated
+2.75%
IDYA - XENE
56%
Loosely correlated
+2.67%
NRIX - XENE
54%
Loosely correlated
+6.63%
ROIV - XENE
51%
Loosely correlated
+0.55%
WVE - XENE
51%
Loosely correlated
+1.13%
More